Are you Dr. Ikoma?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 26 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Naruhiko Ikoma, MD is a general surgeon in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Complex General Surgical Oncology, 2015 - 2018
University of Texas Health Science Center at HoustonResidency, Surgery, 2011 - 2015
Keio Gujuku University School of MedicineClass of 2007
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025- American Board of Surgery Surgery
- American Board of Surgery Complex General Surgical Oncology
- Join now to see all
Publications & Presentations
PubMed
- HIPEC for metastatic gastric cancer: Moving the needle towards 3-year survival.Neal Bhutiani, Y David Seo, Kristen A Robinson, Michael G White, Naruhiko Ikoma
European Journal of Surgical Oncology. 2025-01-01 - 1 citationsRobotic Hepatic Parenchymal Transection Techniques: A Choice Between Imperfect Tools.Jace Landry, Anish J Jain, Ching-Wei Tzeng, Timothy E Newhook, Naruhiko Ikoma
Annals of Surgical Oncology. 2025-01-01 - Phase 1 trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology.Brian Badgwell, Naruhiko Ikoma, Mariela Blum, Xuemei Wang, Jeannelyn Estrella
Cancer. 2025-01-01
Authored Content
- Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020
- Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020
Press Mentions
Six-Time Cancer Survivor: How My Diagnoses Led Me to MD AndersonApril 7th, 2023- Robots Are Taking over Your Surgery (And You Should Be Excited)September 27th, 2023
